Spero Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Spero Therapeutics, Inc. (SPRO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.50% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-12
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.90%.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 1.35%, a 46.64% decline year-over-year.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2019-03-31 was 2.53%.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.80%, a 0.00% change from fiscal 2024.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.80%, a 5.00% decline from fiscal 2023.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.00%, a 135.29% increase from fiscal 2022.
- Spero Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.70%, a 112.50% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.50% 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 3.80% 10-K · filed 2026-03-26 | |||
| 2024-12-31 | 3.80% 10-K · filed 2025-03-27 | |||
| 2023-12-31 | 4.00% 10-K · filed 2025-03-27 | |||
| 2022-12-31 | 1.70% 10-K · filed 2024-03-13 | |||
| 2021-12-31 | 0.80% 10-K · filed 2023-03-30 | |||
| 2020-12-31 | 1.10% 10-K · filed 2022-03-31 | |||
| 2020-09-30 | 1.19% 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | 1.24% 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | 1.35% 10-Q · filed 2020-05-08 | |||
| 2019-12-31 | 2.40% 10-K · filed 2021-03-11 | |||
| 2019-09-30 | 2.42% 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 2.45% 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 2.53% 10-Q · filed 2020-05-08 | |||
| 2018-12-31 | 2.70% 10-K · filed 2020-03-16 | |||
| 2017-12-31 | 2.00% 10-K · filed 2019-03-14 | |||
| 2016-12-31 | 1.30% 10-K · filed 2019-03-14 | |||
| 2015-12-31 | 1.50% 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |